07:02:57 EDT Thu 25 Apr 2024
Enter Symbol
or Name

Login ID:
Lophos Holdings Inc
Symbol MESC
Shares Issued 85,859,673
Close 2024-01-30 C$ 0.08
Market Cap C$ 6,868,774
Recent Sedar Documents

Lophos forms peyote product release specifications

2024-01-31 11:33 ET - News Release

Ms. Claire Stawnyczy reports


Lophos Holdings Inc. has provided further insights into the accomplishments of its wholly owned, subsidiary, Lophos Pharmaceuticals Corp. The subsidiary has achieved a noteworthy milestone in the cultivation and ethical distribution of psychoactive plants and is delighted to announce the formalization of product release specifications for both fresh and dried peyote (Lophophora williamsii).

This significant development underscores our unwavering commitment to quality, consistency, and ethical practices in the cultivation and distribution of peyote.

Stringent Quality Standards:

The product release specifications establish rigorous quality standards, guaranteeing that both fresh and dried peyote consistently adhere to the highest product quality benchmark. These specifications define the product release requirements for Lophos' peyote products, including identity testing, microbiological examination, chemical contamination scrutiny, and quantification of alkaloids.

Moreover, the specifications clearly define the permissible limits for these criteria, aligning with endorsed pharmacopeias recognized by Health Canada, notably the EU Pharmacopeia and the US Pharmacopeia. This steadfast commitment underscores Lophos Pharmaceuticals Corp.'s dedication to delivering products of unparalleled quality to our valued consumers.

Cultivation Uniformity:

Lophos' specifications rigorously test the peyote, striving for uniformity and transparency across different batches. This commitment ensures that Lophos Pharmaceuticals Corp. provides consumers with a consistent and thoroughly tested product they can rely on.

CEO's Vision:

Claire Stawnyczy, CEO of Lophos Pharmaceuticals Corp., expressed enthusiasm about this development, stating, "The establishment of product release specifications is a pivotal step for us. It not only reflects our dedication to product quality but also underscores our commitment to safety in the distribution of peyote."

About Lophos

Lophos Pharmaceuticals Corp., a wholly-owned subsidiary of Lophos Holdings Inc. (CSE:MESC), stands as a prominent biosciences company specializing in the cultivation, research, and sale of peyote. Distinguished by its Controlled Substances Dealers License (CSDL), the subsidiary is authorized for the possession, sale, sending, transportation, and delivery of various controlled substances, including mescaline, psilocin, psilocybin, LSD, DMT, MDMA, and ketamine. Additionally, the license grants permission for the production of mescaline, psilocin, and psilocybin, showcasing the comprehensive scope of our operations.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.